The m6A-regulation and single cell effect pattern in sunitinib resistance on clear cell renal cell carcinoma: Identification and validation of targets

被引:0
|
作者
Deng, Yanxi [1 ]
Wang, Fang [1 ]
Wu, Xinhui [2 ]
Du, Kangming [3 ]
Yang, Qing [3 ]
Xia, Ting [2 ,4 ]
机构
[1] Hosp Chengdu Univ Tradit Chinese Med, Clin Lab, Chengdu, Sichuan, Peoples R China
[2] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China
[3] Hosp Chengdu Univ Tradit Chinese Med, Dept Cardiothorac Surg, Chengdu, Sichuan, Peoples R China
[4] Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China
关键词
epigenetic; sunitinib; ccRCC; MX2; biological; CANCER; IFITM1; PROMOTES;
D O I
10.3389/fphar.2023.1131610
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Sunitinib is the main target drug for clear cell renal cell carcinoma. However, the effect of sunitinib is often limited by acquired drug resistance.Methods: The open-accessed data used in this study were obtained from different online public databases, which were analyzed using the R software. The RNA level of specific genes was detected using quantitative Real-Time PCR. Sunitinib-resistant cell lines were constructed based on protocol get from the previous study. Colony formation and Cell Counting Kit-8 assays were applied to detect cell proliferation ability.Results: In this study, through publicly available data and high-quality analysis, we deeply explored the potential biological mechanisms that affect the resistance of sunitinib. Detailed, data from GSE64052, GSE76068 and The Cancer Genome Atlas were extracted. We identified the IFITM1, IL6, MX2, PCOLCE2, RSAD2 and SLC2A3 were associated with sunitinib resistance. Single-cell analysis, prognosis analysis and m6A regulatory network were conducted to investigate their role. Moreover, the MX2 was selected for further analysis, including its biological role and effect on the ccRCC microenvironment. Interestingly, we noticed that MX2 might be an immune-related gene that could affect the response rate of immunotherapy. Then, in vitro experiments validated the overexpression of MX2 in sunitinib-resistance cells. Colony formation assay indicated that the knockdown of MX2 could remarkably inhibit the proliferation ability of 786-O-Res and Caki-1-Res when exposed to sunitinib.Conclusion: In summary, through publicly available data and high-quality analysis, we deeply explored the potential biological mechanisms that affect the resistance of sunitinib. MX2 was selected for further analysis, including its biological role and effect on the ccRCC microenvironment. Finally, in vitro experiments were used to validate its role in ccRCC.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Genome-wide gene expression profiles of clear cell renal cell carcinoma: Identification of molecular targets for treatment of renal cell carcinoma
    Hirota, Eiji
    Yan, Liang
    Tsunoda, Tatsuhiko
    Ashida, Shingo
    Fujime, Makoto
    Shuin, Taro
    Miki, Tsuneharu
    Nakamura, Yusuke
    Katagiri, Toyomasa
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2006, 29 (04) : 799 - 827
  • [42] Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study
    Paglino, Chiara
    Imarisio, Ilaria
    Ganini, Carlo
    Morbini, Patrizia
    Vercelli, Alessandro
    Bregant, Cristina
    Porta, Camillo
    FUTURE ONCOLOGY, 2012, 8 (12) : 1605 - 1612
  • [43] EFFICACY AND SAFETY OF SUNITINIB IN PATIENTS WITH NON-CLEAR CELL RENAL CELL CARCINOMA
    Lee, J. -L.
    Ahn, J. -H.
    Park, S. H.
    Lim, H. Y.
    Lee, S. H.
    Kim, T. -M.
    Cho, Y. -M.
    Song, C.
    Hong, J. H.
    Kim, C. -S.
    Ahn, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 141 - 141
  • [44] Safety and efficacy of sunitinib for advanced non-clear cell renal cell carcinoma
    Shi, Hong-Zhe
    Tian, Jun
    Li, Chang-Ling
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 (04) : 328 - 333
  • [45] Multifocal Brain Metastases in Clear Cell Renal Cell Carcinoma with Complete Response to Sunitinib
    Zeng, Hao
    Li, Xiang
    Yao, Jin
    Zhu, Yuchun
    Liu, Jiyan
    Yang, Yuru
    Qiang, Wei
    UROLOGIA INTERNATIONALIS, 2009, 83 (04) : 482 - 485
  • [46] VEGF Expression and Response to Sunitinib in Patients with Metastatic Clear Cell Renal Cell Carcinoma
    Minardi, Daniele
    Lucarini, Guendalina
    Santoni, Matteo
    Mazzucchelli, Roberta
    Burattini, Luciano
    Pistelli, Mirco
    Bianconi, Maristella
    Di Primio, Roberto
    Scartozzi, Mario
    Montironi, Rodolfo
    Cascinu, Stefano
    Muzzonigro, Giovanni
    ANTICANCER RESEARCH, 2013, 33 (11) : 5017 - 5022
  • [47] Identification of biological targets of therapeutic intervention for clear cell renal cell carcinoma based on bioinformatics approach
    Yongsheng Chen
    Lichen Teng
    Wenhua Liu
    Yan Cao
    Dexin Ding
    Wentao Wang
    Hui Chen
    Changfu Li
    Ruihua An
    Cancer Cell International, 16
  • [48] Identification of biological targets of therapeutic intervention for clear cell renal cell carcinoma based on bioinformatics approach
    Chen, Yongsheng
    Teng, Lichen
    Liu, Wenhua
    Cao, Yan
    Ding, Dexin
    Wang, Wentao
    Chen, Hui
    Li, Changfu
    An, Ruihua
    CANCER CELL INTERNATIONAL, 2016, 16
  • [49] Validation of ISUP/WHO Grading of Clear Cell Renal Cell Carcinoma
    Dagher, Julien
    Delahunt, Brett
    Rioux-Leclercq, Nathalie
    Egevad, Lars
    Coughlin, Geoff
    Dunglison, Nigel
    Gianduzzo, Troy
    Kua, Boon
    Malone, Greg
    Martin, Ben
    Preston, John
    Pokorny, Morgan
    Wood, Simon
    Samaratunga, Hemamali
    LABORATORY INVESTIGATION, 2017, 97 : 219A - 219A
  • [50] Validation of ISUP/WHO Grading of Clear Cell Renal Cell Carcinoma
    Dagher, Julien
    Delahunt, Brett
    Rioux-Leclercq, Nathalie
    Egevad, Lars
    Coughlin, Geoff
    Dunglison, Nigel
    Gianduzzo, Troy
    Kua, Boon
    Malone, Greg
    Martin, Ben
    Preston, John
    Pokorny, Morgan
    Wood, Simon
    Samaratunga, Hemamali
    MODERN PATHOLOGY, 2017, 30 : 219A - 219A